Bionic Sight Overview
- Founded
-
2012

- Status
-
Private
- Employees
-
4

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2M
- Investors
-
2
Bionic Sight General Information
Description
Developer of a medical device designed to develop and commercialize prosthetic treatments for blindness due to retinal degenerative disease. The company's device uses retinal code that can convert visual images into similar patterns of an action potential that the retina normally produces and can do so across a broad range of stimuli including faces, landscapes, and movement, essentially replicating patterns in a code the brain is expecting and can recognize, enabling users to bring prosthetic capabilities up to the level of near-normal image representation.
Contact Information
Website
www.bionicsightllc.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
- 430 East 63rd Street
- Apartment 2-G
- New York, NY 10065
- United States
+1 (646) 000-0000
Bionic Sight Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Later Stage VC | 01-Mar-2020 | $2M | 000 | Completed | Generating Revenue | |
1. Early Stage VC | 01-Jan-2014 | Completed | Generating Revenue |
Bionic Sight Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Sheila Nirenberg Ph.D | Co-Founder & Principal | ||
William Hauswirth Ph.D | Co-Founder |
Bionic Sight Board Members (1)
Name | Representing | Role | Since |
---|---|---|---|
Stephen Potter | Applied Genetic Technologies | Board Member | 000 0000 |
Bionic Sight Signals
Bionic Sight Investors (2)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Applied Genetic Technologies | Corporation | Minority | 000 0000 | 000000 0 | |
Partnership Fund for New York City | Impact Investing | Minority | 000 0000 | 000000 0 |